Leads Biolabs, a clinical-stage biotech company, has achieved a significant milestone by completing patient enrollment in the pivotal trial for Opamtistomig (LBL-024), a novel PD-L1/4-1BB bispecific antibody aimed at treating extrapulmonary neuroendocrine carcinoma (EP-NEC). This trial, the world’s first registrational clinical study evaluating an immunotherapy monotherapy for EP-NEC, is being led by Professor Shen Lin from Peking University Cancer Hospital and spans across multiple medical centers. Opamtistomig’s efficacy and safety are being evaluated in advanced EP-NEC patients who have failed at least two lines of chemotherapy. EP-NEC is known for being a highly aggressive and immunologically “cold” tumor, with current standard treatments offering limited benefits, emphasizing the critical need for new therapeutic options.
Dr. Charles Cai, the chief medical officer of Leads Biolabs, highlighted Opamtistomig as the first PD-L1/4-1BB-targeted bispecific antibody to reach the pivotal single-arm registrational stage globally. Opamtistomig has shown promising antitumor activity and a favorable safety profile in early trials. The rapid completion of patient enrollment ahead of schedule not only accelerates clinical development timelines but also underscores the urgent patient need for effective and safer therapies. The company remains dedicated to advancing rigorous clinical development across various indications, including EP-NEC, to address unmet medical needs in oncology.
Dr. Xiaoqiang Kang, the founder, chairman, and CEO of Leads Biolabs, attributes this achievement to the exceptional performance of the clinical team, the commitment of investigators, and the trust of patients and their families. The study represents a beacon of hope for patients battling a devastating disease. Guided by the company’s mission of caring for life, focusing on innovation, and fostering win-win cooperation, Leads Biolabs will continue to invest in research and development to expedite Opamtistomig’s global development and deliver transformative therapies worldwide. The urgency to develop novel therapeutic approaches for EP-NEC, given its aggressive nature and limited treatment options, underscores the significance of Opamtistomig’s progress and potential impact on patient outcomes.
Neuroendocrine carcinoma (NEC) comprises poorly differentiated, high-grade neuroendocrine neoplasms that can arise in various sites, including extrapulmonary locations. EP-NEC, characterized by its aggressive and metastatic behavior akin to small cell lung cancer, is often diagnosed at advanced stages, leading to rapid disease progression and poor prognoses. The current standard treatment involves platinum-based chemotherapy, with limited efficacy, especially in platinum-resistant patients. The absence of established second-line therapies highlights the critical need for innovative treatment modalities in EP-NEC, positioning Opamtistomig as a potential game-changer in improving patient outcomes and quality of life.
Leads Biolabs, established in 2012, focuses on discovering, developing, and commercializing innovative therapies to address unmet medical needs in oncology, autoimmune diseases, and other severe conditions globally. The company’s commitment to advancing Opamtistomig’s development underscores its dedication to delivering impactful therapies that can make a difference in patients’ lives. The completion of patient enrollment in the pivotal trial marks a significant step forward in the journey towards addressing the urgent need for effective and safe treatment options in EP-NEC. Leads Biolabs’ relentless pursuit of advancing clinical development and bringing transformative therapies to patients underscores its mission to redefine standards of care and improve outcomes in challenging diseases like EP-NEC.
Key Takeaways:
– Leads Biolabs has completed patient enrollment in the pivotal trial for Opamtistomig, a novel PD-L1/4-1BB bispecific antibody targeting extrapulmonary neuroendocrine carcinoma (EP-NEC).
– Opamtistomig has shown promising antitumor activity and safety in early trials, highlighting its potential to address the unmet medical needs in EP-NEC.
– The completion of patient enrollment ahead of schedule accelerates clinical development timelines and underscores the urgent patient need for effective and safer therapies in EP-NEC.
– Leads Biolabs remains committed to advancing rigorous clinical development to bring transformative therapies like Opamtistomig to patients globally.
Tags: immunotherapy
Read more on pharmabiz.com